Cambridge Cognition Holdings PLC Distribution Agreement with MANUS Neurodynamica (8855B)

TIDMCOG

RNS Number : 8855B

Cambridge Cognition Holdings PLC

22 June 2016

22 June 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Distribution agreement with MANUS Neurodynamica

The neuroscience technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets products and technologies for near-patient cognitive assessment, has entered into a distribution agreement with UK healthcare technology company MANUS Neurodynamica Limited.

The agreement provides Cambridge Cognition with sole rights to market the MANUS Parkinson's Pen, a sensor pen for diagnosis and monitoring of neuromotor impairments, in academic research, pharmaceutical clinical trials and occupational health markets. The CE Class I medical device uses non-invasive, patented technology to record and analyse limb and hand motion to assess underlying neuromotor processes, particularly for patients with Parkinson's disease.

An estimated seven to 10 million people worldwide are living with Parkinson's disease, which is predicted to more than double by the year 2040.(1) The combined direct and indirect cost of Parkinson's is estimated to be nearly $25 billion per year in the United States alone.(2)

Early diagnosis and timely access to specialist care for patients is essential. However, current diagnostic methods for Parkinson's disease are based on a clinician's subjective interpretation or neuroimaging techniques, which are expensive, invasive and require skilled operators. The Parkinson's pen will provide an easy to use, non-invasive alternative.

Following completion of final product enhancements, Cambridge Cognition expects to begin marketing the product initially for use in academic research through its existing global sales channels in Q4 2016. The product will subsequently be marketed for use by healthcare professionals to improve the certainty of differential diagnosis; in pre-symptomatic screening to identify and triage patients at risk and in monitoring disease severity in Parkinson's patients by GPs and specialists in Europe and the US.

Use of the MANUS Parkinson's pen will provide a more accurate low-cost measure in clinical research and provide a direct cost reduction by assisting with a timely, accurate disease diagnosis to enable early treatment and avoid patient deterioration to the stage where intervention costs increase.

Dr Rutger Zietsma, Managing Director of MANUS Neurodynamica: "The pen is a unique product linking over ten years of research with sensor systems and development of data analysis methods for Parkinson's disease. Cambridge Cognition is the perfect partner for MANUS products with their reputation for providing high-end, innovative and clinically validated neuroscientific products and well-established commercial partnerships with leading academic institutions and the biopharmaceutical industry globally. We are very excited about this collaboration and the planned exploitation of our Parkinson's pen product as well as the possibilities of future synergistic product development."

Dr. Steven Powell, Chief Executive Officer, Cambridge Cognition: "Research and development in Parkinson's disease is a key field for Cambridge Cognition and a hugely important area of research. The addition of the MANUS Parkinson's pen to our neurotechnology portfolio enables us to further leverage our investments in commercial channels and allows us to combine world leading cognitive assessments with cutting-edge physical measures as we continue to advance the understanding, diagnosis and treatment of neurological disorders worldwide."

(1) Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V. and Jain, A. (2013), The current and projected economic

burden of Parkinson's disease in the United States. Mov. Disord., 28: 311-318.

(2) Parkinson's Disease Foundation. (2016), Statistics on Parkinson's. www.pdf.org/en/parkinson_statistics.

Enquiries

 
 Cambridge Cognition Holdings plc       www.cambridgecognition.com 
 Steven Powell, Chief Executive         Tel: [phone] 
  Officer                                700 
  Noah Konig, Director of Product        [e-mail] 
  Marketing and Communications 
 
 finnCap Ltd (NOMAD and Joint Broker)   Tel: [phone] 
                                         0500 
 Geoff Nash / Simon Hicks               (Corporate Finance) 
 Alice Lane                             (Corporate Broking) 
 Hybridan LLP (Joint Broker)            Tel: [phone] 
                                         2341 
  Claire Noyce                           (Corporate Broking) 
 
 
   Manus Neurodynamica Ltd                                                            Tel: [phone] 

Rutger Zietsma, Managing director

   Exordium Consulting (Advisor to Manus Neurodynamica)          Tel: [phone] 

Keith Redpath

About Cambridge Cognition

Cambridge Cognition is a leading neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.

For over 30 years the Company's innovative CANTAB(R) technology has advanced the assessment of cognition in global scientific research; clinical trials; and clinical practice, accelerating the development of safe and effective treatments, improving patient outcomes and to helping assess, monitor and manage cognitive health throughout life.

Customers and partners include the world's leading biotechnology and pharmaceutical companies; renowned academic institutions; and public-private healthcare providers.

For further information, visit www.cambridgecognition.com

About MANUS Neurodynamica

Experts in developing, patenting and marketing medical technologies, MANUS Neurodynamica is radically innovating health care management in the emerging field of diagnostics for neuromotor impairments.

The principal product, a sensory pen for diagnosis and monitoring of neuromotor impairments, is a non-invasive, patented technology that records and analyses limb and hand motion to assess the underlying neuromotor processes, particularly for patients with Parkinson's disease.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRBRGDLIDDBGLB

(END) Dow Jones Newswires

June 22, 2016 02:00 ET (06:00 GMT)